Table 2.
Open in new tab

Adjusted Odds Ratios and 95% CIs for the Associations of Continued Antifungal Prophylaxis With Patient Characteristics

No.Multivariate Analysis
C-AFPxN-AFPxAdjusted ORa (95% CI)P Valueb
Recipient sex
 Female95861 [Reference]
 Male122841.56 (.96–2.53).072
Primary diagnosis
 Acute lymphocytic leukemia47381 [Reference]
 Acute myeloid leukemia116671.92 (1.02–3.61).045
 Myelodysplastic syndrome19160.68 (.26–1.81).440
 Others35490.52 (.25–1.09).083
>30 d length of stay
 No921301 [Reference]
 Yes125403.22 (1.93–5.39)<.0001
Maximum grade of GVHD onset from transplant to discharge
 0–11471631 [Reference]
 2–47075.69 (2.33–13.89).0001
>5 d of corticosteroids
 No1291551 [Reference]
 Yes88155.21 (2.69–10.11)<.001
No.Multivariate Analysis
C-AFPxN-AFPxAdjusted ORa (95% CI)P Valueb
Recipient sex
 Female95861 [Reference]
 Male122841.56 (.96–2.53).072
Primary diagnosis
 Acute lymphocytic leukemia47381 [Reference]
 Acute myeloid leukemia116671.92 (1.02–3.61).045
 Myelodysplastic syndrome19160.68 (.26–1.81).440
 Others35490.52 (.25–1.09).083
>30 d length of stay
 No921301 [Reference]
 Yes125403.22 (1.93–5.39)<.0001
Maximum grade of GVHD onset from transplant to discharge
 0–11471631 [Reference]
 2–47075.69 (2.33–13.89).0001
>5 d of corticosteroids
 No1291551 [Reference]
 Yes88155.21 (2.69–10.11)<.001

Abbreviations: GVHD, graft-vs-host disease; C-AFPx, continued antifungal prophylaxis; N-AFPx, no antifungal prophylaxis; OR, odds ratio.

aORs (95% CIs) are from multivariate logistic regression model. Characteristics listed in the table are mutually adjusted.

bBased on Wald test. Bold indicates P < .05.

Table 2.
Open in new tab

Adjusted Odds Ratios and 95% CIs for the Associations of Continued Antifungal Prophylaxis With Patient Characteristics

No.Multivariate Analysis
C-AFPxN-AFPxAdjusted ORa (95% CI)P Valueb
Recipient sex
 Female95861 [Reference]
 Male122841.56 (.96–2.53).072
Primary diagnosis
 Acute lymphocytic leukemia47381 [Reference]
 Acute myeloid leukemia116671.92 (1.02–3.61).045
 Myelodysplastic syndrome19160.68 (.26–1.81).440
 Others35490.52 (.25–1.09).083
>30 d length of stay
 No921301 [Reference]
 Yes125403.22 (1.93–5.39)<.0001
Maximum grade of GVHD onset from transplant to discharge
 0–11471631 [Reference]
 2–47075.69 (2.33–13.89).0001
>5 d of corticosteroids
 No1291551 [Reference]
 Yes88155.21 (2.69–10.11)<.001
No.Multivariate Analysis
C-AFPxN-AFPxAdjusted ORa (95% CI)P Valueb
Recipient sex
 Female95861 [Reference]
 Male122841.56 (.96–2.53).072
Primary diagnosis
 Acute lymphocytic leukemia47381 [Reference]
 Acute myeloid leukemia116671.92 (1.02–3.61).045
 Myelodysplastic syndrome19160.68 (.26–1.81).440
 Others35490.52 (.25–1.09).083
>30 d length of stay
 No921301 [Reference]
 Yes125403.22 (1.93–5.39)<.0001
Maximum grade of GVHD onset from transplant to discharge
 0–11471631 [Reference]
 2–47075.69 (2.33–13.89).0001
>5 d of corticosteroids
 No1291551 [Reference]
 Yes88155.21 (2.69–10.11)<.001

Abbreviations: GVHD, graft-vs-host disease; C-AFPx, continued antifungal prophylaxis; N-AFPx, no antifungal prophylaxis; OR, odds ratio.

aORs (95% CIs) are from multivariate logistic regression model. Characteristics listed in the table are mutually adjusted.

bBased on Wald test. Bold indicates P < .05.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close